Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More
AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
AUROBINDO PHARMA | ASTRAZENECA PHARMA | AUROBINDO PHARMA/ ASTRAZENECA PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 19.6 | 129.8 | 15.1% | View Chart |
P/BV | x | 4.2 | 36.5 | 11.6% | View Chart |
Dividend Yield | % | 0.2 | 0.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
AUROBINDO PHARMA Mar-19 |
ASTRAZENECA PHARMA Mar-18 |
AUROBINDO PHARMA/ ASTRAZENECA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 830 | 1,278 | 64.9% | |
Low | Rs | 527 | 883 | 59.7% | |
Sales per share (Unadj.) | Rs | 333.9 | 228.4 | 146.2% | |
Earnings per share (Unadj.) | Rs | 40.4 | 10.4 | 389.4% | |
Cash flow per share (Unadj.) | Rs | 51.8 | 16.3 | 318.3% | |
Dividends per share (Unadj.) | Rs | 2.50 | 0 | - | |
Dividend yield (eoy) | % | 0.4 | 0 | - | |
Book value per share (Unadj.) | Rs | 237.1 | 98.8 | 240.0% | |
Shares outstanding (eoy) | m | 585.91 | 25.00 | 2,343.6% | |
Bonus/Rights/Conversions | ESOP | - | - | ||
Price / Sales ratio | x | 2.0 | 4.7 | 43.0% | |
Avg P/E ratio | x | 16.8 | 104.2 | 16.1% | |
P/CF ratio (eoy) | x | 13.1 | 66.4 | 19.7% | |
Price / Book Value ratio | x | 2.9 | 10.9 | 26.2% | |
Dividend payout | % | 6.2 | 0 | - | |
Avg Mkt Cap | Rs m | 397,569 | 27,008 | 1,472.1% | |
No. of employees | `000 | 17.9 | 1.4 | 1,316.7% | |
Total wages/salary | Rs m | 25,849 | 1,535 | 1,683.6% | |
Avg. sales/employee | Rs Th | 10,956.9 | 4,210.9 | 260.2% | |
Avg. wages/employee | Rs Th | 1,447.7 | 1,132.2 | 127.9% | |
Avg. net profit/employee | Rs Th | 1,324.3 | 191.1 | 693.1% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 195,636 | 5,710 | 3,426.2% | |
Other income | Rs m | 1,553 | 123 | 1,267.9% | |
Total revenues | Rs m | 197,189 | 5,833 | 3,380.9% | |
Gross profit | Rs m | 39,519 | 463 | 8,537.4% | |
Depreciation | Rs m | 6,680 | 147 | 4,531.5% | |
Interest | Rs m | 2,626 | 0 | - | |
Profit before tax | Rs m | 31,767 | 438 | 7,252.8% | |
Minority Interest | Rs m | 27 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | -881 | 0 | - | |
Tax | Rs m | 7,269 | 179 | 4,062.9% | |
Profit after tax | Rs m | 23,645 | 259 | 9,125.8% | |
Gross profit margin | % | 20.2 | 8.1 | 249.2% | |
Effective tax rate | % | 22.9 | 40.8 | 56.0% | |
Net profit margin | % | 12.1 | 4.5 | 266.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 153,645 | 3,209 | 4,787.6% | |
Current liabilities | Rs m | 120,429 | 2,070 | 5,819.2% | |
Net working cap to sales | % | 17.0 | 20.0 | 85.1% | |
Current ratio | x | 1.3 | 1.6 | 82.3% | |
Inventory Days | Days | 135 | 72 | 186.9% | |
Debtors Days | Days | 64 | 35 | 182.4% | |
Net fixed assets | Rs m | 103,909 | 790 | 13,148.0% | |
Share capital | Rs m | 586 | 50 | 1,171.8% | |
"Free" reserves | Rs m | 138,322 | 2,419 | 5,717.4% | |
Net worth | Rs m | 138,908 | 2,469 | 5,625.4% | |
Long term debt | Rs m | 1,800 | 0 | - | |
Total assets | Rs m | 264,544 | 4,605 | 5,744.2% | |
Interest coverage | x | 13.1 | NM | - | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.7 | 1.2 | 59.6% | |
Return on assets | % | 9.9 | 5.6 | 176.5% | |
Return on equity | % | 17.0 | 10.5 | 162.2% | |
Return on capital | % | 23.8 | 17.7 | 134.4% | |
Exports to sales | % | 49.6 | 0 | - | |
Imports to sales | % | 18.8 | 0 | - | |
Exports (fob) | Rs m | 97,091 | NA | - | |
Imports (cif) | Rs m | 36,741 | NA | - | |
Fx inflow | Rs m | 97,316 | 300 | 32,487.5% | |
Fx outflow | Rs m | 40,589 | 2,015 | 2,014.4% | |
Net fx | Rs m | 56,727 | -1,715 | -3,307.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 16,220 | 88 | 18,453.1% | |
From Investments | Rs m | -28,768 | -94 | 30,735.4% | |
From Financial Activity | Rs m | 19,191 | NA | - | |
Net Cashflow | Rs m | 6,656 | -6 | -116,778.9% |
Indian Promoters | % | 54.1 | 0.0 | - | |
Foreign collaborators | % | 0.0 | 75.0 | - | |
Indian inst/Mut Fund | % | 8.0 | 0.3 | 2,650.0% | |
FIIs | % | 27.7 | 15.7 | 176.4% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 10.2 | 9.1 | 112.1% | |
Shareholders | 69,601 | 12,856 | 541.4% | ||
Pledged promoter(s) holding | % | 8.6 | 0.0 | - |
Compare AUROBINDO PHARMA With: PIRAMAL ENTERPRISES NOVARTIS PANACEA BIOTECH DR. REDDYS LAB GSK PHARMA
Compare AUROBINDO PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Share markets in India are presently trading marginally lower. The BSE Sensex is trading down by 34 points, up 0.1% at 48,844 levels.
J.B.CHEMICALS share price is trading up by 7% and its current market price is Rs 1,066. The BSE HEALTHCARE is up by 1.0%. The top gainers in the BSE HEALTHCARE Index are J.B.CHEMICALS (up 7.2%) and AUROBINDO PHARMA (up 8.0%). The top losers are DR. LAL PATHLABS (down 0.2%) and CAPLIN POINT (down 0.3%).
AUROBINDO PHARMA share price is trading up by 10% and its current market price is Rs 1,021. The BSE HEALTHCARE is up by 1.4%. The top gainers in the BSE HEALTHCARE Index is AUROBINDO PHARMA (up 10.3%). The top losers are NATCO PHARMA (down 0.3%) and ERIS LIFESCIENCES (down 0.4%).
CIPLA share price is trading up by 5% and its current market price is Rs 850. The BSE HEALTHCARE is up by 1.2%. The top gainers in the BSE HEALTHCARE Index are CIPLA (up 5.0%) and AUROBINDO PHARMA (up 9.6%). The top losers are NATCO PHARMA (down 0.2%) and PIRAMAL ENTERPRISES (down 0.6%).
AUROBINDO PHARMA share price has hit an all time high at Rs 1,012 (up 9.4%). The BSE HEALTHCARE Index is up by 1.0%. Among the top gainers in the BSE HEALTHCARE Index today are AUROBINDO PHARMA (up 9.4%) and ABBOTT INDIA (up 0.8%). The top losers include THYROCARE TECHNOLOGIES (down 0.1%) and LAURUS LABS (down 0.2%).
LAURUS LABS share price has hit a 52-week high. It is presently trading at Rs 381. BSE 500 Index is down by 0.2% at 19,022. Within the BSE 500, LAURUS LABS (up 2.5%) and GATEWAY DISTRIPARKS (up 12.4%) are among the top gainers, while top losers are VODAFONE IDEA and APOLLO TYRES.
More Views on NewsIn this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
The budget is just a few weeks away. Which stocks can you expect to move? Find out in this video.
Select smallcaps hold a great potential to become the multibaggers of tomorrow. Here's how you could get in early into these stocks.
More